Sana Dhamija, Suprakash Chaudhury* and Daniel Saldanha

Department of Psychiatry, Dr D Y Patil Medical College, Hospital and Research Centre, Dr D Y Patil Vidyapeeth, Pimpri, Pune

*Corresponding Author: Suprakash Chaudhury, Department of Psychiatry, Dr D Y Patil Medical College, Hospital and Research Centre, Dr D Y Patil Vidyapeeth, Pimpri, Pune.

Received: June 12, 2024; Published: July 01, 2024

Abstract

Subacute sclerosing panencephalitis is a primary progressive chronic neurological disorder associated with demyelination that affects one in a million people in the West, but despite the availability of a widespread measles vaccination, it affects 21 people per million in developing nations like India [1,2]. Measles is primarily an infection that affects children between the ages of one and two. In contrast, SSPE is a long-term side effect that develops from a primary measles infection in a specific group of children and usually manifests six to eight years after the initial infection. This is the mutant measles virus's latent phase, during which it multiplies in neural cells by eluding humoral protection. The development of SSPE is indicative of a malfunctioning cell-mediated immune response during the initial measles infection, which leads to the development of an early humoral immunity and promotes intraneuronal infection [2].

References

1. Garg RK. “Subacute sclerosing panencephalitis”. Postgraduate Medical Journal 916 (2002): 63-70.
2. Gutierrez J., et al. “Subacute sclerosing panencephalitis: an update”. Developmental Medicine and Child Neurology10 (2010): 901-907.
3. Reddy B., et al. “Primary psychiatric manifestations of subacute sclerosing panencephalitis: a case report and literature review”. Psychosomatics 4 (2018): 408-412.
4. Schönberger K., et al. “Epidemiology of subacute sclerosing panencephalitis (SSPE) in Germany from 2003 to 2009: a risk estimation”. PLoS One 7 (2013): e68909.
5. Javali M., et al. “Adult onset subacute sclerosing panencephalitis - Lessons learnt from an atypical presentation”. Journal of Neurosciences in Rural Practice 3 (2014): 310-313.
6. Dayal P and Balhara YP. “Catatonia as presenting clinical feature of subacute sclerosing panencephalitis”. Journal of Pediatric Neurosciences 1 (2014): 57-59.
7. Garg RK., et al. “Subacute sclerosing panencephalitis”. Reviews in Medical Virology 5 (2019): e2058.
8. Nair S., et al. “Adult-onset subacute sclerosing panencephalitis”. Practical Neurology (2021).
9. Garg RK., et al. “The spectrum of psychiatric manifestations in subacute sclerosing panencephalitis: a systematic review of published case reports and case series”. CNS Spectrums 29 (2024): 1-9.
10. Dickerson F., et al. “Antibodies to measles in individuals with recent onset psychosis”. Schizophrenia Research 1-3 (2010): 89-94.
11. Tandra HV., et al. “Subacute sclerosing panencephalitis presenting as choreoathetosis and basal ganglia hyperintensities”. Neurohospitalist1 (2019): 26-29.
12. Lebon S., et al. “An initial MRI picture of limbic encephalitis in subacute sclerosing panencephalitis”. European Journal of Paediatric Neurology 6 (2011): 544-546.
13. Sawaishi Y., et al. “Migratory basal ganglia lesions in subacute sclerosing panencephalitis (SSPE): clinical implications of axonal spread”. Journal of the Neurological Sciences 2 (1999): 137-140.
14. Agarwal A., et al. “Subacute Sclerosing Panencephalitis: A Name with Many Faces”. Annals of Indian Academy of Neurology 6 (2022): 1252-1254.

Citation

Citation: Suprakash Chaudhury. “Psychiatric Manifestations of Subacute Sclerosing Panencephalitis”. Acta Scientific Neurology 7.8 (2024): 01-02.

Copyright

Copyright: © 2024 Suprakash Chaudhury. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.